When was Circio founded?

Circio was founded in 2010 and raised its 1st funding round 14 years after it was founded.

Where is Circio located?

Circio is headquartered in Oslo, Norway.

How many employees does Circio have?

As of Jun 30, 2026, the latest employee count at Circio is 20.

Is Circio a funded company?

Circio is a funded company, having raised a total of $***** in its 1st and only funding round, a Post IPO round on Dec 18, 2024.

When was the latest funding round of Circio?

Circio's latest funding was a $***** Post IPO round on Dec 18, 2024, with participation from 3 investors.

Where does Circio rank among its competitors?

Circio ranks 612th amongst 3277 active competitors, of which 1117 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Circio?

Circio's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Circio - 2026 Company Profile, Funding & Competitors

Circio is a public company based in Oslo (Norway), founded in 2010. It operates as a Developer of immunotherapies for cancer treatment. Circio has raised an undisclosed amount in funding. The company has 3277 active competitors, including 1117 funded and 774 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Developer of immunotherapies for cancer treatment. It offers circular RNA platform for developing medicines based on a modular genetic cassette design for expression of therapeutic proteins directly into cancer cells. It provides a lead candidate ONCOS-102 a monotherapy and in combinations with checkpoint inhibitors for melanoma, and TG01 is an immunotherapy targeting KRAS driver mutations for pancreatic cancer.

Website: www.circio.com/en/
Social
Email ID: *****@circio.com

Key Metrics

Founded Year

2010

Location

Oslo, Norway

Stage

Public

Latest Funding Round

Post IPO, Dec 18, 2024, $*****

Investors

Hoseas & 2 more

Ranked

612^th among 3277 active competitors

Employee Count

20 as on Jun 30, 2026

Similar Companies

Jazz Pharmaceuticals & 2978 more

Exit Details

Public

View Circio's full profile

Circio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Circio Holding ASA CIN: 996162095 , Norway, Active	Aug 09, 2010	-	-

Circio has raised funding over 1 round. Its latest funding round was a Post IPO round on Dec 18, 2024 for $*****. 3 investors participated in its latest round. Circio has 3 institutional investors.

Here is the list of recent funding rounds of Circio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 18, 2024	9363197	Post IPO	2394570	2687169	7685186	8854822

Access funding benchmarks and valuations. Sign up today!

View details of Circio's funding rounds and investors

Circio's employee count trend

Circio has 20 employees as of Jun 26. Here is Circio's employee count trend over the years:

Uncover Circio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Circio include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Circio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Domain Associates, Fidelity Investments & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
612th	Circio 2010, Oslo (Norway), Public	Developer of immunotherapies for cancer treatment	-	Hoseas, Star Kapital & 1 others	49/100